End of Phase-2 meeting
European client entering a pivotal program in a competitive market
- EU based company developing a gastrointestinal product in a competitive and controversial market (opioids)
- The company intends to pursue adaptive Phase 2/3 clinical program to expedite late-stage development
- Company intent to gain agreement from FDA on completion of non-clinical and CMC (quality) program to support marketing approval
Posted:
DownloadStrategy and delivery of global biosimilar development program
Needed expertise for biosimilar regulatory strategy and support with execution
Posted:
Download